drugset / Trial / NCT00813306

14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations

NCT00813306

Phase 1/2 Completed 40 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to assess the safety and tolerability of AZD2066 and to explore the effect of a single dose of AZD2066 on the function of the cardia (the opening between the stomach and the esophagus) compared to placebo (not containing any medical substance) in healthy volunteers.

Timeline

Start
2008-12
Primary completion
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD2066 Small molecule 13 mg Oral